AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis.

Guideline ID: 1681 Published: 2024 Dec

American Gastroenterological Association (AGA) Institute

Singh S, Loftus EV Jr, Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. 2024 Dec;167(7):1307-1343. [102 references] PubMed

View Original Guideline

Overview

Guideline Objective

To provide recommendations on the pharmacological management of moderate-to-severe ulcerative colitis (UC) in outpatients

Patient Population

Adult outpatients with moderate-to-severe UC

Note: These guidelines are intended to apply to patients with moderate-to-severe UC disease activity. This is conventionally defined based on the severity of rectal bleeding and diarrhea. The recommendations in these guidelines do not apply to hospitalized patients with acute severe UC.

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Guidance on pharmacotherapy options for induction and maintenance of remission, including use and positioning of advanced therapies and immunomodulator monotherapy (i.e., thiopurines, methotrexate)
- Consideration for patients who are naïve to or have been exposed to advanced therapies
- Use of combination therapy of biologics and immunomodulators
- Treatment de-escalation and step therapy

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Supplementary Material.
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis; 2024 Dec.
    - Supplementary Material.

- The AGA Institute Process for Developing Clinical Practice Guidelines Part One: Grading the Evidence; 2013 Apr 1.

Implementation Tools

- Spotlight: Pharmacological Management of Moderate-to-Severe Ulcerative Colitis; 2024.
- Ulcerative Colitis Toolkit.
- Related Education.
- The Original Guideline includes the following:
    - Figure 1. Clinical Decision Support Tool: Use and Positioning of Advanced Therapies in the Management of Adult Outpatients with Moderate-to-Severely-Active Ulcerative Colitis (p. 1316)
    - Figure 2. Clinical Decision Support Tool: Use of Combination Therapy and Immunomodulator Therapy, and De-escalation of Therapy in Management of Adult Outpatients with Moderate-to-Severely-Active Ulcerative Colitis (p. 1317)

Patient Education

- Ulcerative Colitis.

Note: This patient information is intended to help patients better understand their health and their diagnosed disorders. Patients and their representatives should still consult with a licensed health care professional for evaluation of treatment options as well as answers to their personal medical questions.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using

these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2025 ECRI